An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: Emerging role of ct-proet-1

Journal of Heart and Lung Transplantation

Volumn 32, Issue 12, 2013, Pages 1214-1221

  Silva Marques, João ^a   Martins, Susana Robalo ^a   Calisto, Carina ^b   Gonçalves, Susana ^a   Almeida, Ana Gomes ^a   De Sousa, João Carvalho ^b   Pinto, Fausto José ^a   Diogo, António Nunes ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b Lisbon Academic Medical Centre   (Portugal)

Author keywords

Biomarkers; Copeptin; Endothelin 1; Natriuretic peptides; Prognosis; Pulmonary hypertension; Troponin

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COPEPTIN; CREATININE; ENDOTHELIN 1; PROADRENOMEDULLIN; PROSTACYCLIN; SILDENAFIL; TROPONIN I; URIC ACID; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK ASSESSMENT; URIC ACID BLOOD LEVEL;

BIOMARKERS; COPEPTIN; ENDOTHELIN-1; NATRIURETIC PEPTIDES; PROGNOSIS; PULMONARY HYPERTENSION; TROPONIN;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; COHORT STUDIES; ECHOCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; TROPONIN I;

EID: 84888010309     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.06.020     Document Type: Article

References (35)

1. G. Simonneau, N. Galie, and L.J. Rubin Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 suppl 2004 5S 12S
2. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
3. A.J. Peacock Primary pulmonary hypertension Thorax 54 1999 1107 1118
4. G.G. Pietra, F. Capron, and S. Stewart Pathologic assessment of vasculopathies in pulmonary hypertension J Am Coll Cardiol 43 suppl 2004 25S 32S
5. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
6. A. Giaid, M. Yanagisawa, and D. Langleben Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1993 1732 1739
7. M. Nootens, E. Kaufmann, and T. Rector Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels J Am Coll Cardiol 26 1995 1581 1585
8. M. Bauer, H. Wilkens, and F. Langer Selective upregulation of endothelin b receptor gene expression in severe pulmonary hypertension Circulation 105 2002 1034 1036
9. S.R. Goldsmith Vasopressin as vasopressor Am J Med 82 1987 1213 1219
10. B. Yanagawa, and N. Nagaya Adrenomedullin: molecular mechanisms and its role in cardiac disease Amino Acids 32 2007 157 164
11. L.B. Yap, D. Mukerjee, and P.M. Timms Natriuretic peptides, respiratory disease, and the right heart Chest 126 2004 1330 1336
12. C. Adlbrecht, M. Hulsmann, and G. Strunk Prognostic value of plasma midregional pro-adrenomedullin and c-terminal-pro-endothelin-1 in chronic heart failure outpatients Eur J Heart Fail 11 2009 361 366
13. S. Neuhold, M. Huelsmann, and G. Strunk Comparison of copeptin, b-type natriuretic peptide, and amino-terminal pro-b-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease J Am Coll Cardiol 52 2008 266 272
14. A. Gegenhuber, J. Struck, and B. Dieplinger Comparative evaluation of b-type natriuretic peptide, mid-regional pro-a-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure J Cardiac Fail 13 2007 42 49
15. A. Peacock, R. Naeije, and N. Galie End points in pulmonary arterial hypertension: the way forward Eur Respir J 23 2004 947 953
16. P.M. Hassoun, S. Nikkho, and E.B. Rosenzweig Updating clinical endpoint definitions Pulmon Circ 3 2013 206 216
17. J. Papassotiriou, N.G. Morgenthaler, and J. Struck Immunoluminometric assay for measurement of the c-terminal endothelin-1 precursor fragment in human plasma Clin Chem 52 2006 1144 1151
18. N.G. Morgenthaler, J. Struck, and B. Thomas Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma Clin Chem 50 2004 234 236
19. N.G. Morgenthaler, J. Struck, and C. Alonso Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay Clin Chem 51 2005 1823 1829
20. N.G. Morgenthaler, J. Struck, and C. Alonso Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
21. W.F. Peacock, R. Nowak, and R. Christenson Short-term mortality risk in emergency department acute heart failure Acad Emerg Med 18 2011 947 958
22. A. Nowak, T. Breidthardt, and M. Christ-Crain Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia Chest 141 2012 974 982
23. C. Rubens, R. Ewert, and M. Halank Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562 1569
24. D. Langleben, R.J. Barst, and D. Badesch Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension Circulation 99 1999 3266 3271
25. T.J. Opgenorth, J.L. Wessale, and D.B. Dixon Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level J Cardiovasc Pharmacol 36 suppl 2000 S292 S296
26. P. Cacoub, R. Dorent, and P. Nataf Endothelin-1 in the lungs of patients with pulmonary hypertension Cardiovasc Res 33 1997 196 200
27. B. Rondelet, F. Kerbaul, and S. Motte Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension Circulation 107 2003 1329 1335
28. T. Masaki Historical review: endothelin Trends Pharmacol Sci 25 2004 219 224
29. J. Struck, N.G. Morgenthaler, and A. Bergmann Proteolytic processing pattern of the endothelin-1 precursor in vivo Peptides 26 2005 2482 2486
30. N. Suzuki, H. Matsumoto, and T. Miyauchi Sandwich-enzyme immunoassays for endothelin family peptides J Cardiovasc Pharmacol 17 suppl 7 1991 S420 S422
31. J.P. Gratton, G. Cournoyer, and B.M. Loffler Et(b) receptor and nitric oxide synthase blockade induce bq-123-sensitive pressor effects in the rabbit Hypertension 30 1997 1204 1209
32. D. Montani, R. Souza, and C. Binkert Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension Chest 131 2007 101 108
33. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
34. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
35. M. Bustamante-Labarta, S. Perrone, and R.L. de la Fuente Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension J Am Soc Echocardiogr 15 2002 1160 1164